amyloidosis

(redirected from AL amyloidosis)
Also found in: Thesaurus, Medical, Encyclopedia.
Related to AL amyloidosis: AA amyloidosis, Cardiac amyloidosis

am·y·loid·o·sis

 (ăm′ə-loi-dō′sĭs)
n.
Any of a group of diseases or conditions characterized by the formation and deposition of amyloid in various organs and tissues of the body.
American Heritage® Dictionary of the English Language, Fifth Edition. Copyright © 2016 by Houghton Mifflin Harcourt Publishing Company. Published by Houghton Mifflin Harcourt Publishing Company. All rights reserved.

amyloidosis

(ˌæmɪlɔɪˈdəʊsɪs)
n
(Pathology) pathol the deposition of amyloid in various tissues of the body, as occurs in certain chronic infections
Collins English Dictionary – Complete and Unabridged, 12th Edition 2014 © HarperCollins Publishers 1991, 1994, 1998, 2000, 2003, 2006, 2007, 2009, 2011, 2014
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.amyloidosis - a disorder characterized by deposit of amyloid in organs or tissues; often secondary to chronic rheumatoid arthritis or tuberculosis or multiple myeloma
illness, sickness, unwellness, malady - impairment of normal physiological function affecting part or all of an organism
Based on WordNet 3.0, Farlex clipart collection. © 2003-2012 Princeton University, Farlex Inc.
Translations

am·y·loi·do·sis

n. amiloidosis, acumulación de amiloide en los tejidos.
English-Spanish Medical Dictionary © Farlex 2012

amyloidosis

n amiloidosis f
English-Spanish/Spanish-English Medical Dictionary Copyright © 2006 by The McGraw-Hill Companies, Inc. All rights reserved.
References in periodicals archive ?
* Caelum Biosciences - CAEL-101 - Light Chain (AL) Amyloidosis: Alexion is collaborating with Caelum Biosciences to develop CAEL-101 for AL amyloidosis, a rare systemic disorder that causes misfolded immunoglobulin light chain protein to build up in and around tissues, resulting in progressive and widespread organ damage.
"This has been one of the largest studies ever conducted in systemic light-chain AL amyloidosis and we are proud to have led it.
M2 PHARMA-June 7, 2019-Takeda Provides Update on TOURMALINE-AL1 Phase 3 Trial in AL Amyloidosis
We also recently reported results from the Phase 3 VITAL study of NEOD001 in AL amyloidosis and are exploring business development opportunities that could result in further clinical investigation of NEOD001." The Company is updating its full year 2019 net cash burn from operating and investing activities, and expects it to be $57-65 million, representing a decrease of approximately $7 million, and expects to end the year with approximately $371 million in cash, cash equivalents and restricted cash (midpoint).
CAEL-101 is a first-in-class amyloid fibril targeted therapy designed to improve organ function by reducing or eliminating amyloid deposits in patients with AL amyloidosis.
The drug is a first-in-class amyloid fibril targeted therapy, aimed at improve organ function by decreasing or eliminating amyloid deposits in patients with AL amyloidosis.
CAEL-101 is a first-in-class amyloid fibril targeted therapy designed to improve organ function by reducing or eliminating amyloid deposits in patients with AL amyloidosis. AL amyloidosis is a rare systemic disorder that causes misfolded immunoglobulin light chain protein to build up in and around tissues, resulting in progressive and widespread organ damage, most commonly to the heart and kidneys.
Another important point is the exclusion of the systemic disease when AL amyloidosis is diagnosed histopathologically.
Primary systemic amyloidosis (AL amyloidosis), which is usually associated with an underlying plasma cell dyscrasia, involves the deposition of insoluble monoclonal immunoglobulin light chains in the skin, muscles, connective tissues, blood vessel walls, peripheral nerves, heart, kidneys, gastro-intestinal tract, and lungs (2).
If AL amyloidosis is present, immunofixation usually demonstrates a monoclonal band, and serum-free light chains show an abnormal kappa/lambda ratio in more than 90% of patients [2].
The two major forms are AL amyloidosis and reactive amyloidosis or amyloid A (AA) amyloidosis, which is due to chronic inflammation.
The most common forms of amyloidosis include systemic AL amyloidosis (formerly primary amyloidosis), systemic AA amyloidosis (formerly secondary amyloidosis), systemic wild-type ATTR amyloidosis (formerly age-related or senile systemic amyloidosis), systemic hereditary ATTR amyloidosis (formerly familial amyloid polyneuropathy), and localized AL amyloidosis (Table 1).